Dogwood Therapeutics, Inc.

This clinical-stage biopharmaceutical company discovers and develops novel therapeutic candidates aimed at treating neuropathy and chronic pain disorders. Its development pipeline features Halneuron, a late-stage non-opioid analgesic derived from tetrodotoxin that selectively inhibits Nav 1.7 sodium channels to alleviate chemotherapy-induced neuropathic pain. Additional programs include SP16, a synthetic anti-inflammatory peptide designed to promote nerve regeneration and reduce nerve damage, alongside preclinical and clinical-stage antiviral therapies, IMC-1 and IMC-2, targeting functional somatic syndromes such as fibromyalgia and Long-COVID. Upon achieving regulatory approval, the company intends to commercialize its pipeline through pharmaceutical distribution partnerships targeting primary care physicians, oncologists, and anesthesiologists.

The enterprise operates as a development-stage entity without commercial revenue and conducts operations across North America and international territories through subsidiaries including Wex Pharmaceuticals, Inc. It oversees clinical development programs across multiple locations, including Phase 2b trial sites in the United States. Technical development activities incorporate contract research and manufacturing relationships with an overseas active ingredient supplier and a Canadian fill-and-finish facility. The provided text does not identify corporate headquarters.

Summary of the business section of Dogwood Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had eight full-time employees and no part-time employees with five employees working in the U.S.”